What was compounded semaglutide?
Compounding pharmacies were producing their own versions of semaglutide — the active ingredient in Ozempic and Wegovy — at a fraction of the brand-name cost. Patients could get compounded semaglutide for $100–150/month compared to $400+ for Wegovy. It was popular, and many people felt it was essentially the same product.
The critical difference: compounded medications are not subject to TGA manufacturing standards. They don't undergo the rigorous quality testing, stability studies, or batch-by-batch verification that licensed pharmaceutical manufacturers must complete.
Why did the TGA ban it?
The TGA cited several concerns that led to the October 2024 ban:
- Contamination risks: Compounding pharmacies don't operate in the same controlled environments as pharmaceutical manufacturing facilities. The risk of microbial or chemical contamination is higher — particularly concerning for an injectable medication.
- Inconsistent dosing: Without standardised manufacturing processes, the actual amount of semaglutide in each dose could vary. Under-dosing means the medication doesn't work; over-dosing increases side effect risk.
- No stability data: TGA-approved medications have proven shelf-life data. Compounded versions may degrade at unknown rates, potentially becoming ineffective or harmful.
- Adverse events: The TGA received reports of adverse events associated with compounded GLP-1 products, though specific numbers haven't been published.
- No clinical evidence: While brand-name semaglutide has data from 15,000+ trial participants, compounded versions have zero clinical trial data.
Is the ban permanent?
The TGA has given no indication it will reverse the ban. As TGA-approved options become more available and potentially PBS-subsidised, the regulatory position is likely to strengthen rather than soften.
What are your options now?
TGA-approved medications only:
- Wegovy ($400–460/mo) — same ingredient as what was compounded, at a verified dose with proven safety data
- Mounjaro ($350–500/mo) — different molecule, higher average weight loss
- Budget options — Duromine (~$100/mo) or Xenical (~$80/mo) for lower-cost alternatives
The lesson
Cheap isn't always safe, especially with injectable medications. The compounding ban was a patient safety measure, even though it made access harder for budget-conscious patients. The real solution is PBS subsidisation — which is now pending for Wegovy.